Compare Stocks: AUPH, PCVX, APGE, and IMVT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.45 -0.1%	$123.46	$35.39 ▼ $134.88	$8.37B	0.34	1.18 million shs	1.26 million shs
AUPH Aurinia Pharmaceuticals	$15.18 -1.7%	$15.92	$10.34 ▼ $19.25	$2.06B	1.42	1.11 million shs	1.59 million shs
IMVT Immunovant	$41.82 -1.8%	$37.98	$14.47 ▼ $42.92	$8.80B	0.77	1.01 million shs	1.36 million shs
PCVX Vaxcyte	$58.86 -1.3%	$54.73	$29.87 ▼ $65.00	$8.88B	1.23	995,145 shs	839,077 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-0.10%	+0.24%	+0.55%	+60.35%	+266.62%
AUPH Aurinia Pharmaceuticals	+0.52%	+1.71%	-3.62%	-2.46%	+36.48%
IMVT Immunovant	+4.08%	+8.45%	+10.08%	+47.10%	+180.08%
PCVX Vaxcyte	+0.73%	+6.67%	+4.59%	+11.43%	+98.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$134.45 -0.1%	$123.46	$35.39 ▼ $134.88	$8.37B	0.34	1.18 million shs	1.26 million shs
AUPH Aurinia Pharmaceuticals	$15.18 -1.7%	$15.92	$10.34 ▼ $19.25	$2.06B	1.42	1.11 million shs	1.59 million shs
IMVT Immunovant	$41.82 -1.8%	$37.98	$14.47 ▼ $42.92	$8.80B	0.77	1.01 million shs	1.36 million shs
PCVX Vaxcyte	$58.86 -1.3%	$54.73	$29.87 ▼ $65.00	$8.88B	1.23	995,145 shs	839,077 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	-0.10%	+0.24%	+0.55%	+60.35%	+266.62%
AUPH Aurinia Pharmaceuticals	+0.52%	+1.71%	-3.62%	-2.46%	+36.48%
IMVT Immunovant	+4.08%	+8.45%	+10.08%	+47.10%	+180.08%
PCVX Vaxcyte	+0.73%	+6.67%	+4.59%	+11.43%	+98.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.19	Hold	$124.43	-7.45% Downside
AUPH Aurinia Pharmaceuticals	2.17	Hold	$17.67	16.38% Upside
IMVT Immunovant	2.50	Moderate Buy	$44.00	5.21% Upside
PCVX Vaxcyte	2.38	Hold	$86.00	46.11% Upside

Current Analyst Ratings Breakdown

Latest AUPH, PCVX, APGE, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/7/2026	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$15.00 ➝ $16.00
8/4/2026	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$47.00 ➝ $50.00
7/29/2026	IMVT Immunovant	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/21/2026	AUPH Aurinia Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2026	APGE Apogee Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	PCVX Vaxcyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	IMVT Immunovant	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	PCVX Vaxcyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/30/2026	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$57.00 ➝ $61.00

(Data available from 8/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.23 per share	N/A
AUPH Aurinia Pharmaceuticals	$283.05M	7.14	$1.00 per share	15.25	$4.62 per share	3.29
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.56 per share	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$18.53 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-32.16%	-30.91%	N/A
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	6.63	17.65	N/A	100.84%	26.11%	19.89%	N/A
IMVT Immunovant	-$505.61M	-$2.82	N/A	N/A	N/A	N/A	-69.59%	-62.49%	N/A
PCVX Vaxcyte	-$766.63M	-$7.63	N/A	N/A	N/A	N/A	-37.56%	-33.62%	N/A

Latest AUPH, PCVX, APGE, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
8/6/2026	Q1 2027	IMVT Immunovant	-$0.6289	-$0.75	-$0.1211	-$0.75	$7.10 million	$7.10 million
8/5/2026	Q2 2026	PCVX Vaxcyte	-$2.06	-$1.97	+$0.09	-$1.97	$12.50 million	N/A
5/20/2026	Q4 2026	IMVT Immunovant	-$0.60	-$0.73	-$0.13	-$0.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	32.59	32.59
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
IMVT Immunovant	N/A	7.27	7.27
PCVX Vaxcyte	N/A	5.72	5.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
AUPH Aurinia Pharmaceuticals	36.83%
IMVT Immunovant	47.08%
PCVX Vaxcyte	96.78%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
AUPH Aurinia Pharmaceuticals	10.40%
IMVT Immunovant	1.90%
PCVX Vaxcyte	3.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
AUPH Aurinia Pharmaceuticals	300	133.05 million	119.21 million	Optionable
IMVT Immunovant	120	206.55 million	202.63 million	Optionable
PCVX Vaxcyte	160	148.80 million	143.89 million	Optionable

AUPH, PCVX, APGE, and IMVT Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX

August 12 at 3:27 AM | marketbeat.com

Bank of America Corp DE Increases Position in Vaxcyte, Inc. $PCVX

August 10 at 3:20 AM | marketbeat.com

Vaxcyte (NASDAQ:PCVX) Upgraded to "Sell" at Wall Street Zen

August 8, 2026 | americanbankingnews.com

Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT)

August 7, 2026 | theglobeandmail.com

Vaxcyte (PCVX) Receives a Buy from Guggenheim

August 7, 2026 | theglobeandmail.com

The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX

August 7, 2026 | marketbeat.com

Vaxcyte, Inc. $PCVX Shares Acquired by Dimensional Fund Advisors LP

August 7, 2026 | marketbeat.com

Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares

August 6, 2026 | insidertrades.com